New Therapeutic Approaches to ART in Pregnancy | Laurent Mandelbrot, MD

International Workshop on HIV & Pediatrics 2017

A Last Barrier to eMTCT: Acute HIV Infection in Pregnancy/Breastfeeding | Alison Drake, MPH, PhD

International Workshop on HIV & Pediatrics 2017

Case Management of Mycobacterial Infections//HIV - High Resource Country | Gareth Tudor-Williams, MD

International Workshop on HIV & Pediatrics 2017

Viral Hepatitis Mother-to-Child Transmission: Applying Lessons from HIV to HBV/HCV | Monique Andersson, MRCP, FRCPath

International Workshop on HIV & Pediatrics 2017

Using Infant Animal Models to Advance Pediatric HIV Prevention, Vaccines and Cure | Ann Chahroudi, MD, PhD

International Workshop on HIV & Pediatrics 2017

Prospects for cure | Annemarie Wensing, MD, PhD

European Meeting on HIV & Hepatitis 2018

What is the place of the monoclonal antibodies in the clinic | Julià Blanco, PhD

European Meeting on HIV & Hepatitis 2018

Reduced drug regimens | Andrea De Luca, MD

European Meeting on HIV & Hepatitis 2018

What’s in the pipeline? Presentations by scientists from the industry | Jean-Marc Steens, MD

European Meeting on HIV & Hepatitis 2018

What’s in the pipeline? Presentations by scientists from the industry | Jean-Marc Steens, MD

European Meeting on HIV & Hepatitis 2018

What’s in the pipeline? Presentations by scientists from the industry | Kathleen Squires, MD

European Meeting on HIV & Hepatitis 2018

What’s in the pipeline? Presentations by scientists from the industry | Kathleen Squires, MD

European Meeting on HIV & Hepatitis 2018

Management of hepatitis C therapy failures - clinical perspective | Sanjay Bhagani, BSc FRCP

European Meeting on HIV & Hepatitis 2018

Management of hepatitis C therapy failures - virological perspective | Francesca Ceccherini– Silberstein, PhD

European Meeting on HIV & Hepatitis 2018

Novel simplified bioinformatics for NGS data analysis | Marc Noguera-Julian, PhD

European Meeting on HIV & Hepatitis 2018

New technologies reaching the clinic | Martin Däumer, MSc

European Meeting on HIV & Hepatitis 2018

Implications for clinical practice | Jonathan Schapiro, MD

European Meeting on HIV & Hepatitis 2018

Clinical trial data 3 vs 2 drug regimens | Andrea De Luca, MD

European Meeting on HIV & Hepatitis 2018

Influence of resistance in the future | Richard Harrigan, MD

European Meeting on HIV & Hepatitis 2018

The current status of PrEP in Europe | Pep Coll, MD

European Meeting on HIV & Hepatitis 2018

A new wild-type HIV in the era of transmitted drug resistance | Kristof Theys, PhD

European Meeting on HIV & Hepatitis 2018

Long acting HIV drugs for prevention: what are the data? | Pep Coll, MD

European Meeting on HIV & Hepatitis 2018

Long acting HIV drugs for treatment: what are the data? | Anton Pozniak, MD, FRCP

European Meeting on HIV & Hepatitis 2018

Improving drug delivery: what are the new technologies? | Saye Khoo, MD, PhD

European Meeting on HIV & Hepatitis 2018